Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ivonescimab + short-course radiotherapy
- Development stage
- Unknown
- Lead developer
- Akeso
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
Ivonescimab + short-course radiotherapy is a combination regimen being investigated for the neoadjuvant treatment of locally advanced rectal cancer (LARC). Ivonescimab (AK112) is a first-in-class humanized tetravalent bispecific antibody that simultaneously targets programmed cell death protein 1 (PD-1) and vascular endothelial growth factor A (VEGF-A). This dual blockade is designed to enhance anti-tumor immune responses while inhibiting angiogenesis and normalizing tumor vasculature. In this regimen, neoadjuvant short-course radiotherapy (SCRT) is administered sequentially followed by ivonescimab, often in combination with CapeOX chemotherapy (oxaliplatin and capecitabine). The goal of this approach is to leverage the immunogenic cell death induced by radiotherapy to prime the immune system, potentially increasing the efficacy of the bispecific checkpoint inhibitor and improving pathological complete response rates.
- Brand names
- Ivonescimab
- Other names
- AK112 + SCRTivonescimab + SCRTAK112 + short-course radiotherapy
02
Targets
PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)
Beyond the preview
Go deeper on ivonescimab + short-course radiotherapy.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ivonescimab + short-course radiotherapy.